Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver

Japanese Journal of Clinical Oncology

Volumn 26, Issue 5, 1996, Pages 341-350

  Marinelli, Andreas ^a   De Brauw, L Maurits ^a   Beerman, Henk ^b   Keizer, H Jan ^a   Van Bockel, J Hajo ^a   Tjaden, Ubbo R ^c   Van De Velde, Cornells J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Colorectal cancer; Isolated liver perfusion; Mitomycin C; Regional chemotherapy; Veno occlusive disease

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ADULT; AGED; ARTICLE; BLOOD; CASE REPORT; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYMOLOGY; FEASIBILITY STUDY; FEMALE; HUMAN; LIVER; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REGIONAL PERFUSION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 0030267755     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.jjco.a023243     Document Type: Article

References (37)

1. Frei E 3rd, Canellos GP: Dose: a critical factor in cancer chemotherapy. Am J Med 69: 585-594, 1980
2. Tattersall MH, Tobias JS: How strong is the case for intensive cancer chemotherapy? Lancet 2: 1071-1072, 1976
3. DeVita VT: Dose-response is alive and well. J Clin Oncol 4: 1157-1159, 1986
4. Hryniuk WM: More is better. J Clin Oncol 6: 1365-1367, 1988
5. Aigner K, Walther H, Tonn J, Wenzl A, Hechtel R, Merker G, Schwemmle K: First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent Results Cancer Res 86: 99-102, 1983
6. Skibba JL, Quebbeman EJ, Komorowski RA, Thorsen KM: Clinical results of hyperthermic liver perfusion for cancer in the liver. Contr Oncol 29: 222-228, 1988
7. Hafström L, Rudenstam C-M, Holmberg SB, Schersten T, Ehrsson H: The pharmacokinetics of melphalan in regional hyperthermic liver perfusion. Reg Cancer Treat 3: 23-25, 1990
8. Ravikumar TS, Pizzorno G, Bodden W, Marsh J, Strair R, Pollack J, Hendler R, Hanna J, D'Andrea E: Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 12: 2723-2736, 1994
9. Muhrer KH, Grimm H: Isolated regional hyperthermal liver perfusion: indications, technique and results. In Cancer Therapy, Beger HG, ed, Springer Verlag Berlin, Heidelberg. p190-200, 1989
10. Marinelli A, Pons DH, Kuppen PJK, Vreeken JA, Tjaden UR, van de Velde CJH: Isolated liver perfusion (ILP) versus hepatic artery infusion (HAI) with 5-fluorouracil (FUra) and mitomycin C (MMC) in a rat model. Proceedings of the American Association for Cancer Research 31: 2547, 1990
11. Doll DC, Weiss RB, Issell BF: Mitomycin: ten years after approval for marketing. J Clin oncol 3: 276-286, 1985
12. Schneider A, Kemeny N, Chapman D, Niedzwiecki D, Oderman P: Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma. Cancer 64: 2203-2206, 1989
13. Marinelli A, Dijkstra FR, van Dierendonck JH, Kuppen PJ, Cornelisse CJ, van de Velde CJH: Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. Br J Cancer 64: 74-78, 1991
14. Aigner KR, Walther H, Link KH: Isolated liver perfusion with MMC/5-FU: surgical technique, pharmacokinetics, clinical results. Contr Oncol 29: 229-246, 1988
15. Runia RD, de Brauw LM, Kothuis BJL, Pauwels EK, van de Velde CJH: Continuous measurement of leakage during isolated liver perfusion with a radiotracer. Nuclear Medicine & Biology 14: 113-118, 1987
16. Tjaden UR, de Bruijn EA, van der Hoeven RA, Jol C, van der Greet J, Lingeman H: Automated analysis of mitomycin in body fluids by high-performance liquid chromatography with on-line sample pretreatment. J Chromatogr 420: 53-62, 1987
17. Lund RH, Newkirk JB: Peritoneovenous shunting system for surgical management of ascites. Contemp Surg 14: 31-45, 1979
18. Lazarus HM, Gottfried MR, Herzig RH, Phillips GL, Weiner RS, Sarna GP, Fay J, Wolff SN, Sudilovsky O, Gale RP, Herzig GP: Veno-occlusive disease of the liver after high-dose mitomycin C therapy an dautologous bone marrow transplantation. Cancer 49: 1789-1795, 1982
19. Shulman HM, McDonald GB, Matthews D, Doney KC, Kopecky KJ, Gauvreau JM, Thomas ED: An analysis of hepatic venocclusive disease and centrilobular hepatic degeneration following bone marrow transplantation. Gastroenterology 79: 1178-1191, 1980
20. Rollins BJ: Hepatic veno-occlusive disease. Am J Med 81: 297-306, 1985
21. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED: The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 39: 603-608, 1985
22. Ayash LJ, Hunt M, Antman K, Nadler L, Wheeler C, Takvorian T, Elias A, Antin JH, Greenough T, Eder JP: Hepatic venoocclusive disease in autologous bone marrow transplantation of solid tumor and lymphomas. J Clin Oncol 8: 1699-1706, 1990
23. van Hazel GA, Scott M, Rubin J, Moertel CG, Eagan RT, O'Connell MJ, Kovach JS: Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treatment Reports 67: 805-810, 1983
24. den Hartigh J, McVie JG, van Oort WJ, Pinedo HM: Pharmacokinetics of mitomycin C in humans. Cancer Res 43: 5017-5021, 1983
25. Verweij J, den Hartigh J, Stuurman M, de Vries J, Pinedo HM: Relationship between clinical parameters and pharmacokinetics of mitomycin C. J Cancer Res Clin Oncol 113: 91-94, 1987
26. Lankelma J, Stuurman M, van Hoogenhuijze J, van Bochove A, Vermorken JB, Verweij J, Pinedo HM: The pharmacokinetic plasma profile of mitomycin C, measured after sequential intermittent intravenous administration. European Journal of Cancer & Clinical Oncology 24:175-180, 1988
27. Schilcher RB, Young JD, Ratanatharathorn V, Karanes C, Baker LH: Clinical pharmacokinetics of high-dose mitomycin C. Cancer Chemother Pharmacol 13:186-190, 1984
28. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987
29. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, Acord P, Lewis BJ: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646-1654, 1989
30. Safi F, Bittner R, Roscher R, Schuhmacher K, Gaus W, Beger GH: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarterial versus continuous intraarterial/intravenous therapy): results of a controlled clinical trial. Cancer 64: 379-387, 1989
31. Wagman LD, Kemeny MM, Leong L, Terz JJ, Hill LR, Beatty D, Kokal WA, Riihimaki DU: A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 8: 1885-1893, 1990
32. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma: a randomized trial. Ann Intern Med 107: 459-465, 1987
33. Kemeny N, Conti JA, Cohen A, Campana P, Huang Y, Shi WJ, Botet J, Pulliam S, Bertino JR: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12: 2288-2295, 1994
34. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Nagorney DM, Tschetter LK, Krook JE: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 125: 1022-1027, 1990
35. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC, Gallot D, Gouzi JL, Pailler JL, Elisa D, Lacaine F, Roos S, Rotman N, Luboinski M, Lasser P: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112-1118, 1992
36. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12: 14-20, 1994
37. Marinelli A, van Dierendonck JH, van Brakel GM, Irth H, Kuppen PJ, Tjaden UR, van de Velde CJH: Increasing the effective concentration of melphalan in experimental rat liver tumours: comparison of isolated liver perfusion and hepatic artery infusion. Br J Cancer 64: 1069-1075, 1991